Mosaic Therapeutics

Mosaic Therapeutics is a biotechnology company focused on developing targeted oncology treatments, specifically focusing on MDM2 antagonists to treat hematological and solid cancers. The company utilizes advanced computational methods and large-scale genomic datasets, including CRISPR-Cas9 genetic screens, to identify and validate novel therapeutic targets. Its lead candidate, ASTX295, is a potent MDM2 antagonist designed for use in combination therapies to suppress oncogenes and induce cell cycle arrest in cancer cells.